CN116370475A - 中枢神经系统病症的治疗 - Google Patents

中枢神经系统病症的治疗 Download PDF

Info

Publication number
CN116370475A
CN116370475A CN202310328785.4A CN202310328785A CN116370475A CN 116370475 A CN116370475 A CN 116370475A CN 202310328785 A CN202310328785 A CN 202310328785A CN 116370475 A CN116370475 A CN 116370475A
Authority
CN
China
Prior art keywords
benzyl
hydroxypiperidin
day
methanone
bipyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310328785.4A
Other languages
English (en)
Chinese (zh)
Inventor
西俊哉
近藤伸一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN116370475A publication Critical patent/CN116370475A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN202310328785.4A 2017-08-31 2018-08-30 中枢神经系统病症的治疗 Pending CN116370475A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762553070P 2017-08-31 2017-08-31
US62/553,070 2017-08-31
CN201880055307.8A CN111065394B (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗
PCT/JP2018/032949 WO2019045121A1 (en) 2017-08-31 2018-08-30 TREATMENT OF CNS DISEASES

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880055307.8A Division CN111065394B (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗

Publications (1)

Publication Number Publication Date
CN116370475A true CN116370475A (zh) 2023-07-04

Family

ID=63722720

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310328785.4A Pending CN116370475A (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗
CN201880055307.8A Active CN111065394B (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880055307.8A Active CN111065394B (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗

Country Status (8)

Country Link
US (4) US11285139B2 (https=)
EP (1) EP3675852A1 (https=)
JP (2) JP7196157B2 (https=)
KR (1) KR102680786B1 (https=)
CN (2) CN116370475A (https=)
CA (1) CA3073925A1 (https=)
MX (1) MX2020001732A (https=)
WO (1) WO2019045121A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3572417B1 (en) 2011-10-14 2025-12-17 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
EP2986624B1 (en) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN117024501A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MX2020004972A (es) 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.
US20210161808A1 (en) * 2018-07-24 2021-06-03 Zenvision Pharma Llp Nasal Drug Delivery System of Brivaracetam or Salt Thereof
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
EP4069685A1 (en) * 2019-12-02 2022-10-12 F. Hoffmann-La Roche AG Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors
GB2597312A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597285A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022217066A1 (en) * 2021-04-09 2022-10-13 The Johns Hopkins University Treatment methods and compositions comprising perampanel
CN115487144A (zh) * 2021-06-18 2022-12-20 北京万全德众医药生物技术有限公司 一种卢非酰胺的口服液制备方法
US20250213547A1 (en) * 2022-03-18 2025-07-03 Takeda Pharmaceutical Company Limited Methods of treating neurological diseases
WO2024100531A1 (en) * 2022-11-07 2024-05-16 Takeda Pharmaceutical Company Limited Method of treating seizure disorders
WO2025126159A1 (en) * 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited A method for treating a neurological disease in a recreational drug user
WO2025257799A1 (en) * 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Methods of treating dravet syndrome
CN121550436A (zh) * 2026-01-23 2026-02-24 四川大学华西医院 新靶点在结节性硬化症相关癫痫中的应用、组合物及联合用药方式

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2014007606A0 (en) 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
HUE039922T2 (hu) 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10562881B2 (en) 2015-10-16 2020-02-18 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound

Also Published As

Publication number Publication date
JP2020532508A (ja) 2020-11-12
US20220168294A1 (en) 2022-06-02
JP7469445B2 (ja) 2024-04-16
KR102680786B1 (ko) 2024-07-02
US20200306238A1 (en) 2020-10-01
WO2019045121A1 (en) 2019-03-07
CN111065394A (zh) 2020-04-24
JP2023027267A (ja) 2023-03-01
KR20200046022A (ko) 2020-05-06
CN111065394B (zh) 2023-03-31
MX2020001732A (es) 2020-03-20
US11285139B2 (en) 2022-03-29
EP3675852A1 (en) 2020-07-08
JP7196157B2 (ja) 2022-12-26
US20230087903A1 (en) 2023-03-23
CA3073925A1 (en) 2019-03-07
US20250281477A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
CN111065394B (zh) 中枢神经系统病症的治疗
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US12097206B2 (en) Method for the treatment of Dravet Syndrome
US20240245631A1 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
Donohue et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol
BR112020002077A2 (pt) usos combinados de lasmiditan e de um antagonista de cgrp na preparação de medicamentos para tratamento de enxaqueca e outras dores de cabeça
JP2022521446A (ja) 発作制御を改善するための製剤
US20230146896A1 (en) Composition and method for treating alzheimer's disease
US20210169835A1 (en) METHODS OF TREATMENT USING AN mTORC1 MODULATOR
JP2015505314A5 (https=)
Wang et al. Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study
US6977253B2 (en) Methods for the treatment of bipolar disorder using carbamazepine
US20060094709A1 (en) Methods for the treatment of bipolar disorder using carbamazepine
HK40083190A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
EA052165B1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination